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n7916 Soluble Fibrin aa a Marker of increaaed Riak in
Acute Coronary Syndromea
M.Galvani, F.Offani, D. Fernni, R. Puggioni, S. Ruggeri, A. Destro,
D. Baccos, P.R.Eisenberg 1. Forrdszior?eCerdiologica Sacco,-Forfi, Italy,
1 Washington University St. Louis, MO, USA
Increases in fibrin formation, reflected by elevations of fibrinopaptide A (FPA)
levels, areassociatad with adverse outcome in patients with unstable angina
(UA) andmyocerdial infarction (Ml). Recently,assayof soluble fibrin has been
proposed to beasensitive marker of fibrin formation and less prone than FPA
to aftifacf associated with sample acquisition. In this study we used a novel
ELlSA (Agen, Brisbane, Australia) based on a capture antibody specific for
a neoepitope exposed on fibrin (y 312-324) to measure soluble fibrin on
admission in 159 patients with acute Coronav syndromes (103 Ml and 56
UA) presenting within 24 hours from the onset of symptoms and with ECG
evidence of myocardial iechemia (?1 mm ST elevation [n = 62], ?1mm ST
depression [n= 36], and Twave inversion [n=39]). The prospectivelydefined
end point of the study was death or non-fatal infarctionheinfarction during the
hospital stay, which occurred in 19 pts (11.9%).There were no differences in
soluble fibrin levels based on ECG criteria (median and quartiles: 2.3 [l.l-
3.9] wgrml -ST elevation, 2.7 [0.6-4.2] @ml- STdepression, 2.0 [0.7-3.6]
pg/ml -T wave inversion; p = ns) or occurrence of Ml (2.0 [0.9-3.6] @ml –
Ml, 2.9 [1.14.1] wg/ml - UA; p = n:). Soluble fibrin was significantly higher in
patients with adverse events, 3.6 [1.5-6.6] #g/ml, vsthose without, 2.1 [0.9-
3.7] wglml (p =0.04). The risk of an event was markedly increased in patients
with the highest tercile of soluble fibrin levels, 7.57. Iowertercile, 7.5% middle,
20.7% highest (p= 0.04). The relative riskof death or non-fatal infarction in
the highest tercile was 1.92 (1.21-3.06) (95% Cl). Increases in soluble fibrin
identify patients with unstable coronary syndromes at high risk for adverse
events who may be candidates for more aggressive antithrombotic therapy.
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Percutsneoua Coronary Intervention
P.D. McGrath, D.E. Wennberg, D.J. Malenke, J.D. Dickens, M.A. Kellett,
T.J. Ryan, Jr., W.A. Bradley, M.J. Hearne, J.F. Robb, S. Shubroeks,
P.VerLee, M.W. Watkins, G.T. O’Connorfor the Northern New England
Cardiovascular Disease Study Group. Lebanon, AH
Controversy exists regarding therelationship behveen individual operator vol-
ume and outcomes in percutaneous coronaty intewentions. Accordingly, we
analyzed a prospectively collected database involving 12,899 interventions
performed by 31 cardiologists at 5 hospitals from 1/2/90 through 12/29/93.
Overall outcames for the group were (%): angiographic success = 69.1,
clinical success = 66.9, new Ml = 2.3, emergency CABG = 2.2, death = 1.0.
Interventionalists were categorized by terciles based on annualized vol-
umea. Median {range) per year: low tercile = 6S {23-S5), middle tercile =
102 {6-143), high tercile = 221 {153-450}. Univariate analyses were usad
to select variables for logistic regressions. Included in the models were com-
binatioris of age, gender, device, comorbidify, EF, pffority, and anatomy as
independent variables.
MuiflvatfsteAna@isOddsRatios(95%Cl)
outcome LowTercile MiddleTercile HighTercile
Analcmaohk SUCCeSS 1.0 1.2 (1.0, 1,4) 2.0 (1.6, 2.S)
Cli;ic;l Success” 1.0 1.2 (1,0, 1.5) 1.6 (1.3, 2.1)
Emergency CABG 1.0 0.S (0.6, 1.2) 0,5(0.3,0.s)
Death 1.0 0,9(0.5,1.7) 0.s (0.4, 1.9)
*z1 lesiondilatsdto <50Y0 stenosisand no Ml, CABG, or death
In this large database, high volume operators were more likely to achieve
angiographic and clinical succeas and avoid emergency CABG with no sig-
nificant difference in rates of Ml or death.
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Anatomical vs. Functional Compiate
Revascularization In Patients with Multivessel
Disease; 1 yaar follow-up in the Multiveaeei PTCA
Multicenter Study
M, Funamoto, O. Katoh, T. Kobayashi, H. Nishikawa, H. Tamai, T. Suzuki for
the Multivessel PTCA Multicenter Study Group. Osaka Medica/ Center for
Carrcerand Cardiovascular Diseases, Osaka, Japan
Itia atill unknown whether revascularization of diseased veasela (Dv) without
ischemia according to Ti-scintigraphy (Tl) affects clinical outcome or not in
the pts with multivessel disease (MVD). The aim of this study is to com-
pare long-term outcome of anatomic (ACR) and functional (FCR) complete
revascularization (CR) by PTCA in pts with MVD. ACR means CR of all DV
regardless of ischemia and FCR ia defined as CR of only iachemia proved
by T1.Study enrollment ended in February 1995. In 4 institutions, 566 pte
met this incluaion criteria [LMT < 50Y0stenosis, more than two major dis-
eaaed vessela including chronic total occluaion (CTO), age <75 ye., no prior
intervention or CABG]. Of these, 96 pts were randomized into two groups;
ACR (49 pts) and FCR (47 pts). This study is to be conducted for 5 yeare
after enrollment. All pts will undergo corona~ angiography (CAG) and TI at
1, 2 and 3 year follow-ups (Y). There were no differences in baseline data
between ACR and FCR [mean age; 62: 61, male; 72: 66Y0, prior Ml; 67:
64%, CTO; 52: 57%,3 vessel disease; 33: 50%, EF; 54: 56% (ACR: FCR)].
Initial success rates of CR were 94% (ACR) and 96% (FCR). No differences
in major in-hospital complications could be found between 2 groups. 1 Y
follow-up rate is 96% (ACR, FCR). There were no differences in cardiac
events between 2 groups [CABG; 2: O%, AMI; 8: 7%, death; 4: 4% (ACR:
FCR)]. No need for further revascularization waa 20: 30% (ACR: FCR). Total
event free ratio is 65: 91% (ACR: FCR). EFat 1 Y was 59: 54% (ACR: FCR).
Conclusion: At 1 Y, there were no clinical or angiographical differences
between ACR and FCR.
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m7923 Target Lesion Ravascuiarization Foilowin,gCoronary
Angioplasty: A Report from the NHLBi PTCA
Regiatry
C.R. Cannan, D.O. Williams, H.A. Cohen, W. Yeh, S.F. Kelsey, KM. Detre.
Rhode Island Hospital, Brown University Providence, Rhode Island, USA,
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
The need to perform target lesion revascularization (TLR) for restenosia is
more representative of the clinical and economic impact of restenosis follow-
ing PTCA than angiographic evidence of lesion recurrence. To charscferfze
and identify predictors of TLR, we analyzed 9-year outcome of2262 pts in the
NHLBI PTCA Registty. TLR was performed in 510/2262 (22.5%) pts. Time
from PTCAto TLR ranged from 1 to 2697 days, median 160 days. TLR waa
by PTCA in 313/510 (61.4%) and CABG in 197/510 (3S.8%). Median time to
PTCA and CABG differed, 134 and 841 daya, respectively (p < 0.05).
AdjustedOdds Ratio 95% Cl.
PredictoraforTLR
Female 0.77”” (0,65, 0,92)
Diabetes Mellitus 1.56*** (1.31, 1.90)
TripleVassel Disease 1.2s”” (1.10, 1.49)
Predictorsfor CABG
TLR Performed>1 yr 5.75”** (4,06, 8.13)
MultivesaelDisease 1.57* (1.07,2.20)
High ‘A StenosisPost PTCA 1.23*** (1.13, 1.33)
*p <0.05, ““ p <0,01, *** p <0.001
Thus, TLRwasobsewad in 1/5 patients. TLR waa more common in males,
diabetics and pts with advanced coronary diaease. The extent of coronary
disease, timing of TLR and PTCA result influenced whether CABG or PTCA
was choaen aa the means of TLR. Pfs at increaeed riak for TLR can be
identified and should be considered for new therapies directed to reduce the
development of reatenosis.
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Foliowing Coronary Angioplasty: Triai Data Versus
Clinical Practice
MM. Gandhi, R.H. Swanton. Depatimenf of Cardiology The Middlesex
Hospital, London, UK
Priortocoronary angioplasty (PTCA), patients are informed of thepotenfialfor
reatenosiaand need for additional revascularization. A recent mete-analysis
of randomized trials of PTCA and the Benestent study suggest that 34% and
